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Protocol
AbstrACt
Introduction Prostate cancer is the most common 
cancer in men in the UK, with nearly 40 000 diagnosed 
in 2014; and it is the second most common cause of 
male cancer-related mortality. The clinical conundrum 
is that most men live with prostate cancer rather than 
die from it, while existing treatments have significant 
associated morbidity. Recent studies have shown very 
low mortality rates (1% after a median of 10-year follow-
up) and no treatment-related reductions in mortality, 
in men with localised prostate cancer. This study will 
identify prognostic factors associated with prostate 
cancer progression to help differentiate aggressive from 
more indolent tumours in men with localised disease 
at diagnosis, and so inform the decision to adopt 
conservative (active surveillance) or radical (surgery or 
radiotherapy) management strategies.
Methods and analysis The Clinical Practice Research 
Datalink (CPRD) contains 57 318 men who were diagnosed 
with prostate cancer between 1 January 1987 and 31 
December 2016. These men will be linked to the Office 
for National Statistics (ONS) and the National Cancer 
Registration and Analysis Service registry databases for 
mortality, TNM stage, Gleason grade and treatment data. 
Men with a diagnosis date prior to 1 January 1987 and 
men with lymph node or distant metastases at diagnosis 
will be excluded. A priori determined prognostic factors 
potentially associated with prostate cancer mortality, 
the end point of cancer progression, will be measured 
at baseline, and the participants followed through to 
development of cancer progression, death or the end of 
the follow-up period (31 December 2016). Cox proportional 
hazards regression will be used to estimate crude and 
mutually adjusted HRs. Mortality risk will be predicted 
using flexible parametric survival models that can 
accurately fit the shape of the hazard function.
Ethics and dissemination This study protocol has 
approval from the Independent Scientific Advisory 
Committee for the UK Medicines and Healthcare products 
Regulatory Agency Database Research (protocol 17_041). 
The findings will be presented in peer-reviewed journals 
and local CPRD researcher meetings.
IntroduCtIon
Prostate cancer is the most commonly diag-
nosed cancer in men, and the second most 
commonly diagnosed cancer in the UK. A 
total of 39 741 new cases of prostate cancer 
were diagnosed in England in 2014, with 
an age-standardised incidence rate of 177.8 
per 100 000 men.1 In the same year, there 
were approximately 11 300 prostate cancer 
deaths in the UK, making prostate cancer 
the second most common cause of cancer 
death in men. Nevertheless, survival rates for 
prostate cancer are relatively high compared 
with other cancer types. The overall 5-year 
age-standardised net survival for men with 
prostate cancer in England was 83.6%, and 
the predicted 10-year survival for men in 
England diagnosed with prostate cancer in 
2015 is 79.9%.2 This suggests that many men 
diagnosed with prostate cancer have indolent 
disease. A key clinical conundrum relates 
to distinguishing men with slow-growing 
tumours that could be managed conser-
vatively with active monitoring from more 
strengths and limitations of this study
 ► The study cohort is drawn from the Clinical Practice 
Research Datalink (CPRD), a large, representative 
UK primary care dataset, with linked cancer registry 
and Office for National Statistics (ONS) data.
 ► Predicting cancer progression is a more clinically 
useful outcome than simply detecting localised 
disease in patients with a disease that is often 
indolent and slow-growing.
 ► Flexible parametric modelling will be used to 
control for the effects of intermediate variables and 
prognostic factor combinations will be used.
 ► Cancer registry data and ONS mortality data are not 
available for the full study period, and CPRD data 
may not be complete.
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aggressive, potentially fatal disease that may require more 
radical intervention.
Prostate cancer can be detected in men in different 
ways. General practitioners (GPs) need to consider the 
possibility of prostate cancer in men presenting with 
lower urinary tract symptoms, erectile dysfunction or 
visible haematuria. Asymptomatic men may also be found 
to have raised prostate-specific antigen (PSA) levels and 
need to be referred for further investigation.3 However, 
the use of PSA as a screening and prognostic biomarker 
remains controversial,4 5 and GPs6–9 and patients10 have 
mixed views about its utility in informing investiga-
tion and treatment decisions for prostate cancer. Other 
screening methods for predicting prostate cancer severity 
have been tested, such as the Stockholm-3 (STHLM-3)
model,11 which did not look at risk of progression and 
relies on genetic biomarkers that are not readily available 
in primary care at this time.
The Bristol-based ProtecT multicentre trial randomised 
men with clinically localised prostate cancer to either 
active monitoring, radical surgery (prostatectomy) or 
radical radiotherapy. After a median of 10-year follow-up 
there was no difference in prostate cancer mortality. 
Overall, the 10-year mortality rates were very low (1%), 
and men randomised to active monitoring were at an 
increased risk of clinical progression and development of 
metastatic disease (22.9 per 1000 person years follow-up) 
compared with the radical treatment arms (8.9 and 9 
per 1000 person years, respectively).12 Men receiving 
surgery or radiotherapy reported more adverse effects 
on urinary, sexual and bowel function compared with the 
active monitoring cohort.13 This was broadly consistent 
with other studies of prostate cancer treatment.14–18 Iden-
tifying factors associated with prostate cancer progression 
may help determine the risk for men having more aggres-
sive prostate cancer, and inform shared decision-making 
about whether to undergo radical treatments or choose 
active monitoring.
Cancer progression is well defined in cancer treat-
ment trials, following the widely used RECIST criteria.19 
However, the concept of cancer progression in prognostic 
studies is much less well defined or consistently applied. 
The ProtecT trial defined prostate cancer progression as 
the occurrence of any of the following events: evidence of 
metastasis, development of T3/T4 disease, commencing 
long-term androgen therapy, ureteric obstruction, rectal 
fistula and new need for catheter.12 Several prognostic 
factors have been identified that may be associated with 
prostate cancer mortality, the endpoint of prostate cancer 
progression. These include demographic,20 genetic,21 
physiological,22 23 comorbidity,24–27 lifestyle,28–33 biochem-
ical34 35 and medication36 37 factors. The strength of 
evidence for these prognostics factors varies and for many 
others it is conflicting.38–44
Primary care medical records contain a wealth of infor-
mation on a patient’s medical history, medications, family 
history and investigation results.45 The Clinical Practice 
Research Datalink (CPRD)46 is a large UK primary care 
research database representative of the general popula-
tion, with links to many other relevant healthcare data 
registries and Office for National Statistics (ONS) data. 
This information is already used for many risk prediction 
tools in primary care settings to predict outcomes and 
inform treatment decisions. Examples include QCancer,47 
which predicts a patient’s absolute risk of future cancer 
diagnosis. To date there are no risk prediction tools for 
cancer progression used in clinical practice.
This study aims to establish which risk factors are asso-
ciated with prostate cancer progression using primary 
care medical records data. These findings, in combina-
tion with metabolomic and genomic data, will inform the 
development of a clinical risk prediction model for the 
progression of prostate cancer following diagnosis.
MEthods And AnAlysIs
Within the CPRD dataset, at least 57 318 men had a diag-
nosis of prostate cancer made between 1 January 1987 
and 31 December 2016, of whom 22 080 have a recorded 
date of death. These men will form the basis of the study 
cohort. Additional mortality, staging (TNM and Gleason 
grade) and treatment data will be obtained by using 
each man’s National Health Service (NHS) number to 
link them to the ONS (available from 1 January 1998) 
and National Cancer Registration and Analysis Service 
(available from 1 January 1990) databases. The index 
date will be the date the diagnosis of prostate cancer was 
first entered into the primary care medical record. From 
this date, the men will be followed until the date of their 
death, the development of prostate cancer progression 
or the end of the cohort period, whichever is later. Men 
with a diagnosis date prior to 1 January 1987 and men 
with lymph node or distant metastases at diagnosis will be 
excluded from the analysis.
Each of the hypothesised prognostic factors for prostate 
cancer mortality identified a priori (see table 1) will be 
recorded as an ‘exposure’ if it is entered into the patient 
record at the study baseline (index date), or recorded 
before the diagnosis of prostate cancer is entered. Contin-
uous variables, such as height, weight and the biochemical 
markers, will be measured according to the most recent 
result prior to the coding of a diagnosis of prostate cancer 
within the study time period. Genetic factors, lifestyle 
exposures, medications and comorbidities will be consid-
ered in a binary manner in relation to their presence or 
absence at the index date. Missing data will be controlled 
for using multiple imputation methods.48
To achieve 95% power and detect a difference in HRs 
of 0.5 in prostate cancer mortality for a binary risk factor 
using an alpha of 0.05, a sample of at least 8762 men with 
prostate cancer would be required, assuming a 1% annual 
mortality rate over a median 10-year follow-up.
The primary outcome measure will be prostate cancer 
mortality. Participants will be presumed to be alive at 
the end of the follow-up period if they have not been 
reported as deceased according to the ONS mortality 
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data. Secondary outcome measures of prostate cancer 
progression will include all-cause mortality, change from 
localised to metastatic disease, and commencing antian-
drogen therapy or chemotherapy. We will use whether 
the treatment recorded in the registry is stated to be local-
ised (ie, one tumour treated) or systemic (ie, more than 
one tumour treated) to help distinguish between early 
and advanced disease.
Descriptive statistics will be used to summarise the 
basic demographic details of the men. The prevalence 
of the preselected putative prognostic factors will be 
calculated and presented. Cox proportional hazards 
regression will be used to estimate the crude and mutu-
ally adjusted HRs (with 95% CI) for prostate cancer and 
all-cause mortality according to the prognostic factors. 
Related prognostic factors, such as smoking and chronic 
obstructive pulmonary disease, will also be grouped to 
account for potential intermediate variables. This anal-
ysis will be repeated with stratification by stage at diag-
nosis. In order to allow for flexibility in the shape of 
the cumulative hazard function, we will use flexible 
parametric survival models49 for prognostic modelling. 
These models incorporate cubic spline terms in the log 
cumulative hazard function and are based on weibull, 
loglogistic or lognormal distributions of survival time. 
We will check for non-linearities in the effects of contin-
uous predictors using fractional polynomials50 and also 
test for time-varying effects of prognostic factors. We will 
determine mortality risk in groups defined by important 
prognostic factors. To asses competing risks, we will use 
cause-specific survival analysis to estimate at 1, 2, 5 and 10 
years post prostate cancer diagnosis the contribution of 
Table 1 Prognostic factors to be assessed
Category Prognostic factor(s) Definition/unit
Basic demographics Age and date of birth Years
Post code GP practice address
Ethnicity ONS ethnicity categories
Physiological Height Centimetres (cm)
Weight Kilograms (kg)
Waist circumference Centimetres (cm)
Waist:hip ratio
Genetic Family history of prostate cancer Recorded diagnosis in first-degree 
or second-degree relative
Biochemical Triglycerides, HDL cholesterol, LDL cholesterol and VLDL 
cholesterol
mmol/L
PSA μ g/L 
HbA1c mmol/L
CRP mg/L
Ferritin μg/L
Haemoglobin g/L
Albumin g/L
Serum glucose and plasma glucose mmol/L
Lead μg/L
Lifestyle Smoking history Smoking tobacco prior to or at index 
date
Relationship status Patient identifies as being in a 
relationship
Alcohol intake Units per week
Medications Simvastatin, atorvastatin, metformin, aspirin, atenolol, bisoprolol, 
sotalol, labetalol, carvedilol, nebivolol, metoprolol, propranolol, 
finasteride, dutasteride, cholecalciferol, ergocalciferol and 
alfacalcidol
Prescribed within the 12 months 
prior to index date
Comorbidities Type 2 diabetes mellitus, ischaemic heart disease, stroke, 
peripheral vascular disease, benign prostatic hypertrophy and 
COPD
Diagnosed prior to index date
COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; GP, General Practitioners; HbA1c, haemoglobin A1c; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; ONS, Office for National Statistics; PSA, Prostate Specific Antigen; VLDL, very-low-density 
lipoprotein. 
group.bmj.com on February 1, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
4 Merriel SWD, et al. BMJ Open 2018;8:e019409. doi:10.1136/bmjopen-2017-019409
Open Access 
prostate cancer mortality to overall mortality in those who 
have died by prognostic factor combinations.51
EthICs And dIssEMInAtIon
This study protocol has approval from the Independent 
Scientific Advisory Committee for the UK Medicines 
and Healthcare products Regulatory Agency Database 
Research (protocol 17_041).
The findings of this study will be submitted as a manu-
script to peer-reviewed journal to aid dissemination to 
clinicians and other researchers in the field. It will also be 
presented and discussed at local CPRD working groups to 
inform other researchers’ methods using the CPRD data-
base. Subsequent studies of the prediction tool, based on 
this piece of research, will involve clinicians at every stage 
to ensure the final tool is acceptable for use in clinical 
practice.
ConClusIons
This study will lay the foundation for the development 
of a clinically useful risk prediction tool. Clinicians will 
be able to use the tool, inputting routine primary care 
data, to improve shared decision-making about an indi-
vidual’s prognosis and, if validated and shown effective in 
trials, inform their practice when deciding with patients 
whether to undergo radical surgery or radiotherapy or be 
followed up conservatively using active monitoring.
Patients will also benefit from this work in other ways. 
They will be able to receive more information from GPs 
and NHS specialists about the risk of progression of their 
prostate cancer, and they will be able to decide within 
a shared decision-making framework with their doctors 
about the potential benefits and harms of undergoing 
radical treatment or active monitoring.
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